摘要
To the Editor:Primary lung cancer is the most commonly diagnosed type ofmalignant tumor and is the leading cause of cancer deathworldwide.Non-small cell lung cancer(NSCLC)makes up 80%to 85%of the overall incidents of primary lung cancer and is classified into two distinct histological subtypes:lung adenocarcinoma(LUAD)and lung squamous cell carcinoma(LUSC).LUAD constitutes nearly 30%to 35%of all primary lung cancer cases,and the recurrence of it seems to be increasing in most countries.[1]As a prevalent mRNA internal modification,N6-methyladenosine(m6A)methylation modification is of great significance for triggering the development of cancer and can be used as a cancer-promoting factor in many cancers.[2,3]In this study,we aim to develop an m6A RNA methylation regulators-premised prognostic signature for LUAD patients.
基金
This study was supported by grants from the National Key R&D Program of China(Nos.2017YFC1311000 and 2018YFC1312100)
the CAMS Initiative for Innovative Medicine(Nos.2017-I2M-1-005,2017-I2M-2-003,and 2019-I2M-2-002)
the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(Nos.2018PT32033 and 2017PT32017)
the Innovation team development project of Ministry of Education(No.IRT_17R10).
